Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting

Di Liu; Leilei Wu; Xiaoling Xu; Shuangyan Yang; Ming Liu; Min Hu; Shengxiang Ren; Yaping Xu

doi:10.1186/s13045-024-01587-w

Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting

J Hematol Oncol. 2024 Sep 13;17(1):84. doi: 10.1186/s13045-024-01587-w.

Authors

Di Liu^#¹, Leilei Wu^#¹, Xiaoling Xu¹, Shuangyan Yang¹, Ming Liu¹, Min Hu¹, Shengxiang Ren², Yaping Xu³

Affiliations

¹ Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR China.
² Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR China. [email protected].
³ Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR China. [email protected].

^# Contributed equally.

Abstract

Combination of immunotherapy with radiotherapy is under active investigation. The PACIFIC trial firmly established the treatment paradigm of consolidation immunotherapy following definitive chemoradiotherapy, inspiring a series of similar or exploratory combination regimens. This summary highlighted six reports updated in the 2024 ASCO Annual Meeting.

Publication types

Congress
Letter

MeSH terms

Chemoradiotherapy / methods
Combined Modality Therapy
Humans
Immunotherapy* / methods
Medical Oncology / methods
Medical Oncology / trends
Neoplasms* / immunology
Neoplasms* / radiotherapy
Neoplasms* / therapy
Societies, Medical

Abstract

Publication types

MeSH terms

Grants and funding